O2 and Mavenir successfully trial technology to improve call clarity for people with hearing loss T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel
The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company LEXINGTON,…
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel
The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company LEXINGTON,…
Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group
FORT LEE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group
FORT LEE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
Parexel Appoints Gwyn Bebb, BM, BCh., Ph.D., to Lead Oncology Clinical Development
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need Parexel Gwyn Bebb,…
Parexel Appoints Gwyn Bebb, BM, BCh., Ph.D., to Lead Oncology Clinical Development
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need Parexel Gwyn Bebb,…
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines PRINCETON, N.J., Sept….
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines PRINCETON, N.J., Sept….
Panbela to Present at the LD Micro Investor Conference
MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
Panbela to Present at the LD Micro Investor Conference
MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to…
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to…
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON…
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON…